What Is an Attenuated Psychotic Symptom? on the Importance of the Context

Schizophrenia Bulletin

Volumn 43, Issue 4, 2017, Pages 687-692

  Fusar Poli, Paolo ^a,b   Raballo, Andrea ^c   Parnas, Josef ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF OSLO   (Norway)

^d Region Hovedstadens Psykiatri   (Denmark)

Author keywords

ARMS; prevention; psychosis; risk; schizophrenia; symptoms

Indexed keywords

ARTICLE; CLINICAL FEATURE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PSYCHOMETRY; PSYCHOSIS; RISK ASSESSMENT; SAMPLING BIAS; SCHIZOPHRENIA; SELF REPORT; SYMPTOM; VALIDITY; PRODROMAL SYMPTOM; PSYCHOLOGICAL RATING SCALE; REPRODUCIBILITY; RISK; STANDARDS;

HUMANS; PRODROMAL SYMPTOMS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; RISK; SELF REPORT;

EID: 85021842898     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbw182     Document Type: Article

References (39)

1. Kempton MJ, Bonoldi I, Valmaggia L, McGuire P, Fusar-Poli P. Speed of psychosis progression in people at ultra-high clinical risk: A complementary meta-analysis. JAMA Psychiatry. 2015;72:622-623.
2. Fusar-Poli P, Byrne M, Badger S, Valmaggia LR, McGuire PK. Outreach and support in south London (OASIS), 2001-2011: Ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis. Eur Psychiatry. 2013;28:315-326.
3. NICE. Psychosis and schizophrenia in children and young people: recognition and management. Periodical. 2013; First published on January 2013.
4. NHS England. Achieving better access to mental health services by 2020. Periodical. 2014.
5. Millan MJ, Andrieux A, Bartzokis G, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15:485-515.
6. Fusar-Poli P, Cappucciati M, Borgwardt S, et al. Heterogeneity of risk for psychosis within subjects at clinical high risk: meta-analytical stratification. JAMA Psychiatry. 2016;73:113-120.
7. Fusar-Poli P, Cappucciati M, Bonoldi I, et al. Prognosis of brief psychotic episodes: A meta-analysis. JAMA Psychiatry. 2016;73:211-220.
8. Fusar-Poli P, Cappucciati M, De Micheli A, et al. Diagnostic and prognostic significance of Brief Limited Intermittent Psychotic Symptoms in subjects at ultra high risk. Schizophr Bull. 2016.
9. Fusar-Poli P, Cappucciati M, Rutigliano G, et al. Towards a standard psychometric diagnostic interview for subjects at ultra high risk of psychosis: CAARMS versus SIPS. Psychiatry J. 2016;2016:7146341.
10. Yung A, Yuen H, McGorry P, et al. Mapping the onset of psychosis: The comprehensive assessment of at-risk mental states. ANZJP. 2005;39:964-971.
11. Nelson B, Simmons MB, Yung AR, et al. Identifying the ultra-high risk (prodromal) population: evaluation of training workshops with mental health services. Aust NZJ Psychiatry. 2008;42:236-243.
12. NICE. Psychosis and schizophrenia in adults: prevention and management. Periodical. 2014; First published on February 2014.
13. Addington J, Stowkowy J, Weiser M. Screening tools for clinical high risk for psychosis. Early Intervention Psychiatry. 2015;9:345-356.
14. Preti A, Cella M, Raballo A. How psychotic-like are unusual subjective experiences Psychol Med. 2011;41:2235-2236.
15. Capra C, Kavanagh DJ, Hides L, Scott J. Brief screening for psychosis-like experiences. Schizophr Res. 2013;149:104-107.
16. Kline E, Thompson E, Demro C, Bussell K, Reeves G, Schiffman J. Longitudinal validation of psychosis risk screening tools. Schizophr Res. 2015;165:116-122.
17. Yung AR, Lin A. Psychotic experiences and their significance. World Psychiatry. 2016;15:130-131.
18. Schultze-Lutter F, Renner F, Paruch J, Julkowski D, Klosterkötter J, Ruhrmann S. Self-reported psychotic-like experiences are a poor estimate of clinician-rated attenuated and frank delusions and hallucinations. Psychopathology. 2014;47:194-201.
19. Fusar-Poli P, Cappucciati M, Rutigliano G, et al. At risk or not at risk A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry. 2015;14:322-332.
20. Michel C, Schultze-Lutter F, Schimmelmann BG. Screening instruments in child and adolescent psychiatry: general and methodological considerations. Eur Child Adolesc Psychiatry. 2014;23:725-727.
21. Fusar-Poli P, Schultze-Lutter F. Predicting the onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning. Evid Based Ment Health. 2016;19:10-15.
22. Werbeloff N, Drukker M, Dohrenwend BP, et al. Selfreported attenuated psychotic symptoms as forerunners of severe mental disorders later in life. Arch Gen Psychiatry. 2012;69:467-475.
23. Kobayashi H, Nemoto T, Koshikawa H, et al. A self-reported instrument for prodromal symptoms of psychosis: Testing the clinical validity of the PRIME Screen-Revised (PS-R) in a Japanese population. Schizophr Res. 2008;106:356-362.
24. Therman S, Lindgren M, Manninen M, et al. Predicting psychosis and psychiatric hospital care among adolescent psychiatric patients with the Prodromal Questionnaire. Schizophr Res. 2014;158:7-10.
25. Zammit S, Kounali D, Cannon M, et al. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am J Psychiatry. 2013;170:742-750.
26. Fusar-Poli P, Rutigliano G, Stahl D, et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry. 2016.
27. Fusar-Poli P, Schultze-Lutter F, Cappucciati M, et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. 2016;42:732-743.
28. Kaymaz N, Drukker M, Lieb R, et al. Do subthreshold psychotic experiences predict clinical outcomes in unselected nonhelp-seeking population-based samples A systematic review and meta-analysis, enriched with new results. Psychol Med. 2012;42:2239-2253.
29. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:1022-1031.
30. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58:158-164.
31. Lee J, Rekhi G, Mitter N, et al. The Longitudinal Youth at Risk Study (LYRIKS)-an Asian UHR perspective. Schizophr Res. 2013;151:279-283.
32. Loewy RL, Johnson JK, Cannon TD. Self-report of attenuated psychotic experiences in a college population. Schizophr Res. 2007;93:144-151.
33. Parnas J. The core Gestalt of schizophrenia. World Psychiatry. 2012;11:67-69.
34. Preti A, Cella M, Raballo A. All that shines is not psychosis: A cautionary note on the assessment of psychotic symptoms in childhood and adolescence. Psychol Med. 2012;42:1787-1788.
35. Nordgaard J, Sass LA, Parnas J. The psychiatric interview: validity, structure, and subjectivity. Eur Arch Psychiatry Clin Neurosci. 2013;263:353-364.
36. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it Mol Psychiatry. 2012;17:1174-1179.
37. Parnas J, Bovet P. Psychiatry made easy: operation(al)ism and some of its consequences. In: Kendler KS, Parnas J, eds. Philosophical Issues in Psychiatry III: The Nature and Sources of Historical Changes. Oxford: Oxford University Press; 2015:190-212.
38. Rietdijk J, Klaassen R, Ising H, et al. Detection of people at risk of developing a first psychosis: comparison of two recruitment strategies. Acta Psychiatr Scand. 2012;126:21-30.
39. Calkins M, Moore T, Satterthwaite T, et al. Persistence of psychosis spectrum symptoms in the Philadelphia Neurodevelopmental Cohort: A prospective two year followup. World Psychiatry. In press 2017.